In Segment A, individuals will receive unique doses and schedules of oral ABBV-744 pill to recognize safe dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 might be given as "include-on" therapy. In Section C, https://jaidenpdozl.bloguerosa.com/31126704/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled